TREM1 and aortic aneurysm: Our group and others have developed a pharmacological TREM-1 blocker, LR-12, which has been shown to provide benefits in experimental chronic diseases, including atherosclerosis (16) and aortic aneurysm (34), as well as in acute injury, including sepsis and acute MI (15).